This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Puig, P. Articles by Di Como, C. J. Search for Related Content PubMed PubMed Citation Articles by Puig, P. Articles by Di Como, C. J. Related Collections Commentary

p73 Expression in Human Normal and Tumor Tissues

Loss of p73 Expression Is Associated with Tumor Progression in Bladder Cancer

¹ Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, and
² Department of Biological Sciences, Columbia University, New York, New York

Purpose: To characterize the expression profile of p73 in human normal tissues by immunohistochemistry (IHC) and to analyze the correlation between p73 expression and bladder cancer progression.

Experimental Design: CJDp73 was characterized for p73 detection in Western blot and IHC through its application to isoform-transfected 293 cells. Normal tissues were analyzed by IHC with the CJDp73 antiserum. Transitional cell carcinoma (TCC)-derived cell lines were subjected to reverse transcription-PCR and Western blot. TCC tissue microarrays were analyzed for p73 expression by IHC, and the results were statistically analyzed.

Results: p73 immunostaining was nuclear and restricted to epithelial cells of certain organs such as squamous epithelium of the epidermis and transitional epithelium of the bladder. The expression was also observed in certain specialized glandular epithelia such as acinar cells of breast and parotid gland. Four of seven TCC-derived cell lines had low to undetectable p73 protein levels. We found undetectable or low p73 expression in 104 of 154 (68%) TCC cases, this phenotype being more frequently observed in invasive tumors when compared with superficial lesions. This association was statistically significant (P < 0.0001). We also observed a significant association between p53, p63, and p73 alterations with bladder cancer progression (P < 0.0001).

Conclusions: p73 plays a tumor suppressor role in bladder cancer, and its inactivation occurs through an epigenetic mechanism, most probably involving protein degradation.

Commentary

The Role of p63 and p73 in Tumor Formation and Progression: Coming of Age Toward Clinical Usefulness: Commentary re: F. Koga et al., Impaired p63 Expression Associates with Poor Prognosis and Uroplakin III Expression in Invasive Urothelial Carcinoma of the Bladder. Clin. Cancer Res., 9: 5501–5507, 2003, and P. Puig et al., p73 Expression in Human Normal and Tumor Tissues: Loss of p73 Expression Is Associated with Tumor Progression in Bladder Cancer. Clin. Cancer Res., 9: 5642–5651, 2003.

Ute M. Moll
Clin. Cancer Res. 2003 9: 5437-5441. [Full Text] [PDF]

This article has been cited by other articles:

				Y. Ma, W.-D. Yu, P. A. Hershberger, G. Flynn, R.-X. Kong, D. L. Trump, and C. S. Johnson 1{alpha},25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model Mol. Cancer Ther., September 1, 2008; 7(9): 3047 - 3055. [Abstract] [Full Text] [PDF]

				J. Johnson, J. Lagowski, A. Sundberg, S. Lawson, Y. Liu, and M. Kulesz-Martin p73 Loss Triggers Conversion to Squamous Cell Carcinoma Reversible upon Reconstitution with TAp73{alpha} Cancer Res., August 15, 2007; 67(16): 7723 - 7730. [Abstract] [Full Text] [PDF]

				S. Gonzalez, M. M. Perez-Perez, E. Hernando, M. Serrano, and C. Cordon-Cardo p73{beta}-Mediated Apoptosis Requires p57kip2 Induction and IEX-1 Inhibition Cancer Res., March 15, 2005; 65(6): 2186 - 2192. [Abstract] [Full Text] [PDF]

				U. M. Moll and N. Slade p63 and p73: Roles in Development and Tumor Formation Mol. Cancer Res., July 1, 2004; 2(7): 371 - 386. [Abstract] [Full Text] [PDF]

				U. M. Moll The Role of p63 and p73 in Tumor Formation and Progression: Coming of Age Toward Clinical Usefulness: Commentary re: F. Koga et al., Impaired p63 Expression Associates with Poor Prognosis and Uroplakin III Expression in Invasive Urothelial Carcinoma of the Bladder. Clin. Cancer Res., 9: 5501-5507, 2003, and P. Puig et al., p73 Expression in Human Normal and Tumor Tissues: Loss of p73{alpha} Expression Is Associated with Tumor Progression in Bladder Cancer. Clin. Cancer Res., 9: 5642-5651, 2003. Clin. Cancer Res., November 15, 2003; 9(15): 5437 - 5441. [Full Text] [PDF]